Micypra

Cyproterone acetate, the active ingredient in Micypra, is a combined oral contraceptive presented as a tablet for oral use. Together with ethinylestradiol, it provides estrogen and progestogen activity to prevent pregnancy and to manage androgen‑dependent skin conditions in women of reproductive age.

GNH USA supplies Micypra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Micypra, a combined estrogen‑progestogen oral contraceptive, is used in hormonal regulation of reproductive and androgen‑dependent conditions.

- Contraception: prevents ovulation and pregnancy in women of child‑bearing age. - Acne: reduces androgen‑driven acne lesions. - Hirsutism: diminishes excess facial and body hair growth.

Micypra may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea - Headache - Breast tenderness - Spotting or irregular bleeding

Serious or Rare Side Effects: - Deep vein thrombosis - Pulmonary embolism - Severe hypertension

Before prescribing Micypra, consider the following precautions. - Pregnancy: contraindicated due to teratogenic risk (Category X). - Smoking: avoid in women over 35 who smoke heavily. - Cardiovascular disease: assess thrombotic risk prior to use. - Liver disease: use with caution in hepatic impairment. - Drug interactions: review concomitant medications for CYP3A4 inducers. - Store at ambient temperature: keep below 25°C, in the original pack, protected from moisture.

Micypra can interact with several medicines; monitoring is advised.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce contraceptive efficacy. - Anticoagulants (e.g., warfarin): may increase clotting risk.

Moderate Interactions (Monitor Closely): - Antiepileptics (e.g., valproate): may alter hormone levels. - Antifungals (e.g., ketoconazole): may increase plasma concentrations. - Certain antibiotics (e.g., tetracycline): may slightly diminish effectiveness.